Jonathan Davies

Cooley successfully defeated a patent infringement suit for its client Vifor (International) AG, a pioneer in iron deficiency and anemia therapies. The Cooley IP litigation team representing Vifor was led by intellectual property (IP) litigation partners Sanya Sukduang and Jonathan Davies, with support from cyber/data/privacy partner Tiana Demas and IP litigation associates John Habibi and Bonnie Fletcher Price.

Cooley successfully defeated an inter partes review on behalf of Liquidia Technologies, a biopharmaceutical company focused on the development and commercialization of products to treat pulmonary hypertension, in United Therapeutics Corp. v. Liquidia Technologies Inc., case number 22-2133, in the US Court of Appeals for the Federal Circuit, relating to Liquidia’s high blood pressure drug patent.

Cooley successfully defeated an emergency motion for injunction for Samsung in Alexion Pharmaceuticals, Inc. et al. v. Samsung Bioepis Co. Ltd. before District Judge Gregory Williams in ongoing Biologics Price Competition and Innovation Act (BPCIA) litigation for its proposed biosimilar Soliris, which is used to treat blood disorders.

Cooley successfully defeated a preliminary injunction filed by United Therapeutics that sought to block the launch of client Liquidia’s Yutrepia (treprostinil) inhalation powder for treatment of pulmonary hypertension associated with interstitial lung disease.

Cooley successfully lifted a Hatch-Waxman injunction for Liquidia Technologies, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products, enabling Liquidia to launch its new drug, Yutrepia.